HDAC9 and inflammatory bowel disease: The anti-inflammatory properties of this HDAC inhibitor, combined with its ability to modulate immune cell function, provide a mechanistic rationale for the observed therapeutic synergy and support its potential as an adjunctive therapy in IBD management.